New crown sequelae animal model, construction method and application thereof
By constructing a zebrafish model of recombinant SARS-CoV-2 protein and utilizing in vivo fluorescence imaging technology and reactive oxygen species (ROS) evaluation indicators, the challenges of simulating residual damage from SARS-CoV-2 and screening drugs were solved, enabling rapid, safe, and low-cost drug screening and evaluation.
Patent Information
- Application Number
- CN202411317324.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-20
- Publication Date
- 2024-11-12
AI Technical Summary
Existing technologies are insufficient to quickly, safely, and effectively simulate the widespread and persistent damage caused by the residual effects of the novel coronavirus in the body, and drug screening systems suffer from high risks, high costs, and long cycles.
A zebrafish model of COVID-19 sequelae was constructed by injecting recombinant SARS-CoV-2 protein into zebrafish. In vivo fluorescence imaging technology was used to evaluate the therapeutic effect of drugs, and reactive oxygen species were used as evaluation indicators to screen for effective drugs.
It enables rapid, accurate, and safe evaluation and screening of drugs that have therapeutic effects on the sequelae of COVID-19. It is low-cost, suitable for high-throughput screening, and cost-effective, filling a gap in drug screening and evaluation.
Smart Images

Figure CN118923588A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of animal models for COVID-19 sequelae, and specifically to an animal model for COVID-19 sequelae, a construction method and its application. Background Art
[0002] After infection with the new coronavirus, the virus replicates in large quantities in the human body and attacks everywhere. There are currently reports in the literature that the virus affects multiple organs, including the brain, eyes, heart, lungs, and kidneys. During and after the new coronavirus, the remaining components of the new coronavirus will cause long-term and persistent damage to the body. After each infection, the residual components of the new coronavirus will remain in the human body for at least 8-12 months, accompanied by various persistent physical injuries, namely the symptoms of post-COVID sequelae, also known as long COVID. According to scientific statistics, there are at least 36 symptoms of post-COVID sequelae, including fatigue, sleep disorders, heart problems, new persistent coughs, and brain fog. Unfortunately, even one year after the onset of post-COVID sequelae, only 29% of the population feel fully recovered.
[0003] The sequelae of the new coronavirus will be an urgent problem that will plague the public for a long time.
[0004] Drug screening is an important part of the drug development process. For the infection and damage caused by the new coronavirus, we can start from the perspectives of prevention, blocking the transmission route, inhibiting virus replication, or neutralizing the virus. We can also start from the perspective of reducing, preventing, and treating the damage caused by the new coronavirus. At present, the screening systems related to the new coronavirus are mostly focused on how to block the invasion stage of viral infection or interfere with the replication stage after infection. The systems use live viruses, pseudoviruses, or human trials. The content of the virus components used is complex, and the conditions for conducting the experiment are not universal. The hazards and possible risks in the screening process are relatively large, the cycle is long, and the cost is high.
[0005] The invention patent with application number 2023111378056 discloses a method for constructing and applying a model of olfactory nerve damage in zebrafish larvae caused by the S protein of the new coronavirus, and belongs to the technical field of animal model construction. The construction method includes: taking transgenic zebrafish larvae with different fluorescent markers of GABAergic neurons and neutrophils 3 to 10 days after fertilization, administering SARS-CoV-2 virus S1 protein intranasally after anesthesia for infection, and then resuscitating; 3 to 24 hours after modeling, combining in vivo fluorescence imaging technology to select larvae with significant differences in fluorescence intensity compared with uninfected, which is the model. This patent constructs a model of olfactory damage in the infection stage of the new coronavirus, which is aimed at the virus infection stage model. Its main purpose is to screen drugs that can prevent new coronavirus infection and virus invasion stages, and mainly the olfactory nerves.
[0006] However, the patent mainly infects zebrafish in vitro, only targets the infection stage, and is limited to the olfactory nerve. It does not study the model of extensive and persistent damage caused by the novel coronavirus components remaining in the body after the novel coronavirus infection is completed or even after the patient recovers. Therefore, the patent only studies the zebrafish olfactory nerve during the novel coronavirus infection stage in vitro. This is completely different from the model of the patent, which specializes in the novel coronavirus components remaining in the body after the novel coronavirus infection is completed or even after the patient recovers, causing extensive and persistent damage.
[0007] At the same time, the characteristic of COVID-19 sequelae is that COVID-19 residues remain in the body for a long time, mainly in various organs and blood. Therefore, it is urgent to establish a method for evaluating and screening the effect of drugs in treating COVID-19 sequelae, which can not only simulate the damage of COVID-19 components in the body well, but also quickly and conveniently evaluate and screen drugs for treating COVID-19 sequelae. The modeling is simple, safe and effective, which has important practical application value. Summary of the invention
[0008] The present application provides an animal model of COVID-19 sequelae, a construction method and its application, which can quickly and accurately evaluate and screen drugs that have therapeutic effects on COVID-19 sequelae.
[0009] The technical solution adopted by this application to solve its technical problems is: an animal model of COVID-19 sequelae, including: zebrafish injected with COVID-19 recombinant protein, the injection concentration of the COVID-19 recombinant protein is ≥1ng / tail, and the purity of the injected COVID-19 recombinant protein is >50%. The COVID-19 sequelae animal model is used to evaluate and screen drugs that have therapeutic effects on COVID-19 sequelae.
[0010] This application can be used to evaluate the toxicity or efficacy of known drugs, such as various inducers, therapeutic drugs, health products, functional foods, etc., and can also be used to screen unknown drugs, develop new drugs, new structures, new formulas, and new treatment methods. It can well simulate the damage of new coronavirus components in the body, and can quickly and conveniently evaluate and screen drugs for the treatment of new coronavirus sequelae. The modeling is simple, safe and effective, with great application value. It can reliably, quickly, efficiently and accurately reflect the actual situation of the drug in the body, has high cost performance, and fills the gap in the screening and evaluation methods of new coronavirus sequelae drugs at home and abroad.
[0011] Preferably, the purity of the injected SARS-CoV-2 recombinant protein is >90%.
[0012] Preferably, the purity of the injected SARS-CoV-2 recombinant protein is >95%.
[0013] Preferably, the zebrafish is a zebrafish 5 days after fertilization.
[0014] Preferably, the recombinant proteins of the new coronavirus include at least one of the recombinant S protein of the new coronavirus, the recombinant N protein of the new coronavirus, and the recombinant M protein of the new coronavirus.
[0015] Preferably, the injection site for injecting the recombinant SARS-CoV-2 protein into the zebrafish is the yolk sac or blood vessels. The injection time is after 5 dfp of the zebrafish. The SARS-CoV-2 components are directly injected into the yolk sac and blood vessels, so that they flow with the blood and cause extensive damage in the body. This is more in line with the characteristics of SARS-CoV-2 sequelae and is aimed at studying the extensive damage caused by SARS-CoV-2 residues in the body during the recovery and healing stages.
[0016] Preferably, the recombinant protein of the new coronavirus is expressed and purified via a prokaryotic system, yeast system, insect system or mammalian system.
[0017] Preferably, the SARS-CoV-2 recombinant protein is expressed and purified using a mammalian protein expression system.
[0018] Preferably, the SARS-CoV-2 recombinant protein used is expressed and purified using a 293 expression system or a CHO expression system.
[0019] A method for constructing an animal model of COVID-19 sequelae, which is used to construct an animal model of COVID-19 sequelae as mentioned above, culture zebrafish in water, and inject the zebrafish with recombinant protein of the new coronavirus.
[0020] A method for evaluating and screening drugs for COVID-19 sequelae, using the COVID-19 sequelae animal model as described above as an animal model, comprises the following steps: Step 1: Set up a normal control group: culture zebrafish in water; Step 2: Set up the model group: Cultivate zebrafish of the same specifications as in the step in water, and inject the zebrafish with the recombinant protein of the new coronavirus to create a model; Step 3: Set up the sample group to be tested: Cultivate the zebrafish of the same specifications as in step 1 in water, and inject the SARS-CoV-2 recombinant protein and the drug sample to be tested into the yolk sac or blood vessels of the zebrafish; Step 4. Detection and evaluation: Take zebrafish from the normal control group, model group and test sample group for testing, compare the evaluation indicators of each test drug in the test sample group and the model group, and evaluate the efficacy of the test drug in treating or regulating the sequelae of COVID-19.
[0021] Preferably, the evaluation index includes at least one of: immune cell improvement effect, active oxygen index improvement effect, cell apoptosis improvement effect, and pathology improvement effect.
[0022] Preferably, the immune cell improving effect includes neutrophil improving effect, macrophage improving effect, T cell improving effect, B cell improving effect, immune cell specific functional factors and immune cell specific surface markers, immune cell specific functional factors such as TNF-α, IL-2.
[0023] Preferably, the improvement effect of active oxygen indexes includes: improvement effect of active oxygen, improvement effect of nitric oxide and other oxidative damage indexes. The improvement effect of active oxygen reflects the degree of oxidative stress in zebrafish by detecting the accumulation of hydrogen peroxide in zebrafish or the fluorescence intensity of oxygen free radicals. During the detection, fluorescent photographs of the whole zebrafish or the zebrafish yolk sac are collected for analysis.
[0024] Preferably, the evaluation formula is: the efficacy of the drug in improving the sequelae of COVID-19 = (model group - test sample group) / (model group - normal control group) × 100%.
[0025] Preferably, according to different experimental purposes and requirements, one of the evaluation indicators can be selected for evaluation, or multiple indicators can be selected for comprehensive evaluation. The evaluation criteria of the present application are as follows: when the significance difference level of the evaluation indicator of the test sample group relative to the model group is p < 0.05, the drug has a significant effect on improving the sequelae of COVID-19; otherwise, the drug does not have the effect of improving the sequelae of COVID-19 or the effect is not obvious.
[0026] The substantial effects of this application are: (1) This COVID-19 sequelae animal model uses living zebrafish as model animals and test animals, which can truly reflect the pharmacological effects and pharmacokinetic characteristics of drugs in vivo in the context of overall biological activity. Zebrafish larvae are small in size, measuring 1-4 mm, and can be analyzed in microplates, such as 96-well plates and 384-well plates, to meet the needs of high-throughput, automated rapid screening; (2) The cost of using zebrafish for the COVID-19 sequelae animal model is low. Compared with monkeys, dogs, and mice as animal carriers, the cost of using zebrafish as an experimental carrier for screening experiments is less than 0.1 yuan per day. The zebrafish experiment has a short development cycle, a high number of eggs laid at a time, and small differences in offspring from the same parent. It is suitable for batch experiments, which is conducive to eliminating individual differences. It also has good stability and repeatability, and the experimental operation is simple; (3) This animal model of COVID-19 sequelae uses an appropriate dose of the recombinant N protein of the SARS-CoV-2 to model, eliminating the interference of other complex components of the SARS-CoV-2, which is conducive to understanding the characteristic damage caused by a single component of the SARS-CoV-2 and is more conducive to finding targeted drugs; (4) In this COVID-19 sequelae drug evaluation and screening method, since reactive oxygen species are widespread throughout the body, using body characteristics as an evaluation indicator is conducive to evaluating the precise effects of drugs in a wide range of COVID-19 injuries. Using a fluorescent probe of reactive oxygen species as a test indicator provides a relatively stable and reliable observation indicator; (5) This COVID-19 sequelae animal model can be used to evaluate the toxicity or efficacy of known drugs, such as various inducers, therapeutic drugs, health products, functional foods, etc. It can also be used to screen the toxicity or efficacy of unknown drugs, new drug development, new structures, new formulas, new treatment methods, etc., and has great application value; (6) This COVID-19 sequelae drug evaluation and screening method is a brand-new drug evaluation model and evaluation method for COVID-19 sequelae. It can reliably, quickly, efficiently and accurately reflect the actual situation of the drug in the body. It is cost-effective and fills the gap in COVID-19 sequelae drug screening and evaluation methods at home and abroad. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 It is the fluorescence image of the normal group, the COVID-19 sequelae group and the drug combination A in Example 1 of the present application; Figure 2 It is a fluorescence intensity percentage diagram of the normal group, the COVID-19 sequelae group and the drug combination A in Example 1 of the present application; Figure 3 This is a time chart of screening 500 drugs for treating sequelae of COVID-19 in Example 2 of the present application; Figure 4 This is the cost chart for screening 500 drugs for treating COVID-19 sequelae in Example 2 of the application. DETAILED DESCRIPTION
[0028] The technical solution of the present application is further described below through specific embodiments. Embodiment 1
[0029] The infection characteristics of the new coronavirus are a relatively long-term and continuous infection rate, and a wide range of cells available for infection in the host population. Among them, the various viral components that make up the new coronavirus each perform their own functions, such as interacting with the host, evading the host's inherent immunity, promoting inflammatory responses, and overproducing reactive oxygen species (ROS), causing extensive tissue and cell damage throughout the body. Therefore, after recovery from the new coronavirus, the body still faces a relatively long detoxification process. The new coronavirus components remaining in the body may continue to cause physical disorders and damage, leading to various new coronavirus sequelae. Therefore, the treatment of new coronavirus sequelae is also very critical. This application is aimed at the study of extensive damage to the body caused by new coronavirus residues during the recovery and healing stages.
[0030] A method for evaluating and screening drugs for sequelae of COVID-19, the specific steps are as follows: Step 1: Set up a normal control group: culture zebrafish 5 days post fertilization (5 dfp) in water; Step 2: Set up the model group: Cultivate the zebrafish of the same specifications as in the step in water, and inject the zebrafish with the recombinant N protein of the new coronavirus to create a model. The injection concentration of the recombinant N protein of the new coronavirus is ≥1ng / tail, and the purity of the recombinant N protein of the new coronavirus is >90%; Step 3. Set up the sample group to be tested: Cultivate the zebrafish of the same specifications as in step 1 in water, and inject the recombinant N protein of the new coronavirus and drug combination A into the yolk sac or blood vessels of the zebrafish to evaluate and screen the therapeutic effect of drug combination A on the sequelae of the new coronavirus; Step 4. Detection and evaluation: Take zebrafish from the normal control group, model group and test sample group for testing, compare the evaluation indicators of each test drug in the test sample group and the model group, and evaluate the efficacy of the test drug in treating or regulating the sequelae of COVID-19.
[0031] It should be noted that the recombinant protein of the new coronavirus can also be selected from at least one of the recombinant N protein of the new coronavirus or the recombinant M protein of the new coronavirus. The recombinant protein of the new coronavirus needs to be expressed and purified by a prokaryotic system, a yeast system, an insect system or a mammalian system. In this embodiment, the recombinant N protein of the new coronavirus is expressed and purified by a mammalian protein expression system, for example, by a 293 expression system or a CHO expression system.
[0032] It should also be noted that when evaluating the efficacy of the drug to be tested in treating or regulating the sequelae of the new crown, the evaluation indicators include: at least one of the following: improvement of immune cells, improvement of reactive oxygen indexes, improvement of cell apoptosis, and improvement of pathology. Among them, the improvement of immune cells includes improvement of neutrophils, improvement of macrophages, improvement of T cells, improvement of B cells, specific functional factors of immune cells, and specific surface markers of immune cells. The improvement of reactive oxygen indexes includes improvement of reactive oxygen species, improvement of nitric oxide, and other oxidative damage indicators. The improvement of reactive oxygen species reflects the degree of oxidative stress in zebrafish by detecting the accumulation of hydrogen peroxide in the zebrafish or the fluorescence intensity of oxygen free radicals. During the detection, fluorescent photographs of the whole zebrafish or the zebrafish yolk sac are collected for analysis. According to different experimental purposes and requirements, you can choose one of them for evaluation, or you can choose multiple indicators for comprehensive evaluation.
[0033] Existing studies have found that the residual components of the new coronavirus can widely damage various organs and tissues of the body. Based on the extensive damage to the body caused by the components of the new coronavirus, the new coronavirus sequelae animal model of the present application may also include but is not limited to the following evaluation indicators, such as nerve damage and improvement, memory and cognitive ability damage and improvement, major organ damage and improvement, etc. In short, the drug evaluation and screening method constructed based on the new coronavirus sequelae animal model of the present invention should be included in the scope of the present invention.
[0034] When evaluating drug combination A, the efficacy of drug combination A in improving the sequelae of COVID-19 = the efficacy of drug combination A in improving the sequelae of COVID-19 = (model group - test sample group) / (model group - normal control group) × 100%. When the significance difference level of the evaluation index of the test sample group relative to the model group is p < 0.05, drug combination A has a significant effect in improving the sequelae of COVID-19; otherwise, drug combination A does not have the effect of improving the sequelae of COVID-19 or the effect is not obvious.
[0035] like Figure 1-2 As shown, in this embodiment, by injecting the components of the new coronavirus into zebrafish, an animal model of new crown sequelae is constructed, and then the fluorescent probe H2DCFH-DA is used to detect reactive oxygen species (ROS), which can evaluate whether the sample has the effect of resisting the damage of the new coronavirus N protein. The H2DCFH-DA fluorescent probe has no fluorescence, and is oxidized by intracellular reactive oxygen species (ROS) to generate fluorescent DCF. Therefore, in this experiment, the more severe the oxidative damage (new crown sequelae) of the zebrafish to the recombinant N protein of the new coronavirus, the stronger the total fluorescence intensity of the zebrafish. If the sample has the effect of treating new crown sequelae, the better the therapeutic effect, the more the total fluorescence intensity of the zebrafish is weakened. It is observed that after administering drug combination A, the fluorescence intensity is significantly reduced compared with the new crown sequelae group, indicating that the reactive oxygen species (ROS) are significantly reduced and there is no significant difference with the normal group, indicating that drug combination A has a better effect of treating new crown sequelae. Embodiment 2
[0036] The animal model of COVID-19 sequelae of the present application was compared with the animal model of rats or mice, and the effects of 500 drugs on the treatment of COVID-19 sequelae were evaluated at the same time, such as Figure 3 and 4 As shown, the COVID-19 sequelae animal model only takes one week to screen and evaluate 500 candidate drugs, while the mouse model requires at least four weeks and the rat model requires at least four weeks. This shows that the COVID-19 sequelae animal model is significantly superior to the traditional rat and mouse systems in terms of screening time. The COVID-19 sequelae animal model only costs 2,000 yuan to screen and evaluate 500 candidate drugs, while the mouse model requires at least 100,000 yuan and the rat model requires at least 150,000 yuan. Therefore, the COVID-19 sequelae animal model is significantly superior to the traditional rat and mouse systems in terms of screening cost.
[0037] The above-described embodiment is only a preferred solution of the present application and does not limit the present application in any form. There are other variations and modifications without exceeding the technical solution described in the claims.
Claims
1. An animal model of COVID-19 sequelae, characterized in that: include: The zebrafish injected with the recombinant protein of the new coronavirus, the injection concentration of the recombinant protein of the new coronavirus is ≥1ng / tail, and the purity of the injected recombinant protein of the new coronavirus is >50%. The animal model of post-COVID-19 sequelae is used to evaluate and screen drugs that have therapeutic effects on post-COVID-19 sequelae.
2. The animal model of COVID-19 sequelae according to claim 1, characterized in that: The zebrafish were 5 days post fertilization.
3. The animal model of COVID-19 sequelae according to claim 1, characterized in that: The recombinant proteins of the new coronavirus include: at least one of the recombinant S protein of the new coronavirus, the recombinant N protein of the new coronavirus, and the recombinant M protein of the new coronavirus.
4. The animal model of COVID-19 sequelae according to claim 1 or 3, characterized in that: The injection site for injecting the recombinant protein of the new coronavirus into zebrafish is the yolk sac or blood vessels, and the injection time is after the zebrafish is 5 dfp.
5. The animal model of COVID-19 sequelae according to claim 1, 2 or 3, characterized in that: The recombinant protein of the new coronavirus is expressed and purified through prokaryotic systems, yeast systems, insect systems or mammalian systems.
6. A method for constructing an animal model of COVID-19 sequelae, used for constructing an animal model of COVID-19 sequelae as described in any one of claims 1 to 5, characterized in that: include: The zebrafish were cultured in water and injected with the recombinant protein of the new coronavirus.
7. A method for evaluating a drug for COVID-19 sequelae, used to evaluate an animal model for COVID-19 sequelae as described in any one of claims 1 to 6, characterized in that: The following steps are involved: Step 1: Set up a normal control group: culture zebrafish in water; Step 2: Set up the model group: Cultivate zebrafish of the same specifications as in the step in water, and inject the zebrafish with the recombinant protein of the new coronavirus to create a model; Step 3: Set up the sample group to be tested: Cultivate the zebrafish of the same specifications as in step 1 in water, and inject the SARS-CoV-2 recombinant protein and the drug sample to be tested into the yolk sac or blood vessels of the zebrafish; Step 4. Detection and evaluation: Take zebrafish from the normal control group, model group and test sample group for testing, compare the evaluation indicators of each test drug in the test sample group and the model group, and evaluate the efficacy of the test drug in treating or regulating the sequelae of COVID-19.
8. The method for evaluating drugs for sequelae of COVID-19 according to claim 7, characterized in that: The evaluation indicators include: at least one of: immune cell improvement effect, reactive oxygen index improvement effect, cell apoptosis improvement effect, and pathology improvement effect. The immune cell improvement effect includes neutrophil improvement effect, macrophage improvement effect, T cell improvement effect, B cell improvement effect, immune cell specific functional factors, and immune cell specific surface markers.
9. The method for evaluating drugs for post-COVID-19 sequelae according to claim 7, characterized in that: The improvement effects of active oxygen indicators include: improvement of active oxygen, improvement of nitric oxide and other oxidative damage indicators. The improvement effect of active oxygen reflects the degree of oxidative stress in zebrafish by detecting the accumulation of hydrogen peroxide in zebrafish or the fluorescence intensity of oxygen free radicals. During the detection, fluorescent photos of the whole zebrafish or zebrafish yolk sac are collected for analysis.
10. The method for evaluating drugs for sequelae of COVID-19 according to claim 9, characterized in that: The evaluation criteria are: when the significance difference level of the evaluation index of the test sample group relative to the model group is p < 0.05, the drug has a significant effect in improving the sequelae of COVID-19; otherwise, the drug does not have the effect of improving the sequelae of COVID-19 or the effect is not obvious.
Citation Information
Patent Citations
Construction method and application of visual mouse model for monitoring functions of specific CTLs of SARS-CoV-2 Spike protein S1
CN113073113A
Construction method and application of new coronavirus S protein induced zebra fish fry olfactory nerve injury model
CN117379530A
Method for constructing novel coronavirus infection model and application thereof
CN117384957A
Model construction method for forming troxerutin and salvianolic acid C regulating stress particles and inhibiting new crown N protein from infecting cells
CN118638193A
